Sponsors (56)
Introduced April 9, 2025 by Brian K. Fitzpatrick · Last progress April 9, 2025
The bill directs meaningful, targeted federal investments to accelerate brain tumor research, trial access, and survivorship care—potentially improving outcomes for patients—while increasing federal spending and creating tradeoffs around resource concentration, administrative burdens, data/privacy risks, and clinical safety that may limit or unevenly distribute those benefits.
Patients with brain tumors (including glioblastoma and pediatric patients) will get increased, targeted federal funding and programs that accelerate development and testing of new therapies (e.g., cellular immunotherapies), increasing the number of clinical trials and chances of new approved treatments.
Researchers, scientists, and medical centers gain more stable funding, better access to biospecimens and data, and collaboration tools that expand research capacity and speed translation from lab to early‑phase clinical trials.
Patients and families (especially in rural and high‑risk communities) will have improved awareness of clinical trial options and biomarker testing, plus culturally and linguistically appropriate outreach that can increase informed treatment choices and trial enrollment.
Taxpayers face increased federal spending (tens of millions per year across multiple program authorizations) without offsets, raising budgetary commitments.
Researchers and other patient populations may be affected if concentrating funding on glioblastoma and cellular immunotherapies diverts NIH resources and investigator attention away from other cancers or broader research areas.
Hospitals, research centers, and small community providers will face administrative and compliance burdens (reporting biospecimens, applying for/implementing pilots), which can impose costs and favor larger institutions over smaller or rural providers.
Based on analysis of 12 sections of legislative text.
Requires NIH reporting of brain‑tumor biospecimens, creates NCI research networks and CAR‑T team awards, funds outreach and survivorship pilots, and directs FDA guidance to reduce trial exclusions.
Creates new federal requirements and programs to speed research, improve care, and increase awareness about brain tumors. It requires public reporting of NIH-funded brain tumor biospecimen collections, directs the NIH/NCI to fund new multi‑institutional research networks and team awards for glioblastoma and cellular immunotherapy (including CAR‑T), funds public outreach and survivor-care pilot programs, and directs FDA to issue guidance to reduce exclusion of brain tumor patients from clinical trials.